Anacardic acid for neural repair

12083,134

17/267608

August 12, 2019

Methods for stimulating neural repair and remyelination and for treating a myelin related disorder in a subject are described. The methods include administering to a subject in need of treatment an effective amount of anacardic acid having the formula (I) of claim 1 or a pharmaceutically acceptable salt thereof.

Vanderbilt University (Nashville, TN, US)

1. A method of stimulating neural repair in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of anacardic acid (AA) having the structure: [chemical expression included] or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein AA is administered to the subject.

3. The method of claim 1 , wherein the subject has been diagnosed as having a demyelinating disorder.

4. The method of claim 2 , wherein the demyelinating disorder is multiple sclerosis.

5. The method of claim 1 , wherein the subject has been diagnosed as having an infection causing demyelination.

6. The method of claim 1 , wherein AA is administered with a pharmaceutically acceptable carrier.

7. The method of claim 1 , wherein the effective amount of AA that is administered is between 250-1500 mg AA a day.

8. A method of stimulating remyelination in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of AA or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein the subject has been diagnosed as having a demyelinating disorder.

10. The method of claim 9 , wherein the demyelinating disorder is multiple sclerosis.

11. The method of claim 8 , wherein the subject has been diagnosed as having an infection causing demyelination.

12. The method of claim 11 , wherein the infection causing demyelination is human immunodeficiency virus infection.

13. The method of claim 8 , wherein AA is administered with a pharmaceutically acceptable carrier.

14. The method of claim 8 , wherein the effective amount of AA that is administered is between 250-1500 mg AA a day.

15. A method of treating a myelin related disorder in a subject in need thereof, comprising administering to the subject an effective amount of AA or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , wherein the myelin related disorder is multiple sclerosis.

17. The method of claim 15 , wherein the myelin related disorder is an injury to the spinal cord.

18. The method of claim 15 , wherein the myelin related disorder is a cerebral infarction.

19. The method of claim 15 , wherein the myelin related disorder is post-infectious encephalomyelitis.

20. The method of claim 15 , wherein the effective amount of AA that is administered is between 250-1500 mg AA a day.

5240962 August 1993 Nakatsu
20110250303 October 2011 Nagashima
20150045330 February 2015 Inoue
20170095436 April 2017 Bjornsson
20170107218 April 2017 Zhou
20170362231 December 2017 Ibrahim
08048621 February 1996
08291110 November 1996
09221473 August 1997
2016100858 June 2016

Ljunggren-Rose, A. et al., PNAS, Sep. 1, 2020, vol. 117, No. 35, p. 21527-21535; printed from www.pnas.org/cgi/doi/10.1073/pnas.2006566117 on Sep. 21, 2023. cited by examiner
International Search Report and Written Opinion dated Nov. 1, 2019 for corresponding International Application No. PCT/US19/46119. cited by applicant
National Center for Biotechnology Information. “PubChem Compound Summary for CID 167551, Anacardic acid” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Anacardic-acid. Accessed Jan. 21, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/167551. cited by applicant
Reich, Daniel S et al. “Multiple Sclerosis.” The New England journal of medicine vol. 378,2 (2018): 169-180. doi:10.1056/NEJMra1401483. cited by applicant
Noseworthy, J H et al. “Multiple sclerosis.” The New England journal of medicine vol. 343,13 (2000): 938-52. doi:10.1056/NEJM200009283431307. cited by applicant
Wingerchuk, Dean M et al. “The spectrum of neuromyelitis optica.” The Lancet. Neurology vol. 6,9 (2007): 805-15. doi:10.1016/S1474-4422(07)70216-8. cited by applicant
Rovaris, M., et al., “Secondary progressive multiple sclerosis: current knowledge and future challenges.” he Lancet. Neurology vol. 5,4, (2006): 343-54. cited by applicant
Compston, Alastair, and Alasdair Coles. “Multiple sclerosis.” Lancet (London, England) vol. 372,9648 (2008): 1502-17. doi:10.1016/S0140-6736(08)61620-7. cited by applicant
Franklin, Robin J M, and Charles Ffrench-Constant. “Remyelination in the CNS: from biology to therapy.” Nature reviews. Neuroscience vol. 9,11 (2008): 839-55. doi: 10.1038/nm2480. cited by applicant
Mahad, Don H et al. “Pathological mechanisms in progressive multiple sclerosis.” The Lancet. Neurology vol. 14,2 (2015): 183-93. doi:10.1016/S1474-4422(14)70256-X. cited by applicant
Carvalho, Ana Laura Nicoletti et al. “Acute, subacute toxicity and mutagenic effects of anacardic acids from cashew (Anacardium occidentale Linn.) in mice.” Journal of ethnopharmacology vol. 135,3 (2011): 730-6. doi:10.1016/j.jep.2011.04.002. cited by applicant
Balasubramanyam, Karanam et al. “Small molecule modulators of histone acetyltransferase p300.” The Journal of biological chemistry vol. 278,21 (2003): 19134-40. doi:10.1074/jbc.M301580200. cited by applicant
Hemshekhar, Mahadevappa et al. “Emerging roles of anacardic acid and its derivatives: a pharmacological overview.” Basic & clinical pharmacology & toxicology vol. 110,2 (2012): 122-32. doi:10.1111/j.1742-7843.2011.00833.x. cited by applicant
Philip, Joseph Y N et al. “Isolation of anacardic acid from natural cashew nut shell liquid (CNSL) using supercritical carbon dioxide.” Journal of agricultural and food chemistry vol. 56,20 (2008): 9350-4. doi:10.1021/jf801532a. cited by applicant
Trevisan, M T S et al. “Characterization of alkyl phenols in cashew (Anacardium occidentale) products and assay of their antioxidant capacity.” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association vol. 44,2 (2006): 188-97. doi:10.1016/j.fct.2005.06.012. cited by applicant
Natarajan, Chandramohan et al. “TLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin Repair.” PloS one vol. 11,3 e0152163. (Mar. 29, 2016) doi:10.1371/journal.pone.0152163. cited by applicant
Sriram, S., et al., “IL-33 expression in MS: Role in Remyelination and repair.” Neurology, 2016. Abstract presented at the American Academy of Neurology, 2016. cited by applicant
Bai, C Brian et al. “A mouse model for testing remyelinating therapies.” Experimental neurology vol. 283, Pt A (2016): pp. 330-340. doi: 10.1016/j.expneurol.2016.06.033. cited by applicant
Deshmukh, Vishal A et al. “A regenerative approach to the treatment of multiple sclerosis.” Nature vol. 502,7471 (2013): 327-332. doi:10.1038/nature12647. cited by applicant
Magalon, Karine et al. “Olesoxime accelerates myelination and promotes repair in models of demyelination.” Annals of neurology vol. 71,2 (2012): 213-26. doi:10.1002/ana.22593. cited by applicant
Lassmann, Hans, and Monika Bradl. “Multiple sclerosis: experimental models and reality.” Acta neuropathologica vol. 133,2 (2017): 223-244. doi: 10.1007/s00401-016-1631-4. cited by applicant
Satoh, M et al. “Synthesis of anacardic acids, 6-[8(Z), 11(Z)-pentadecadienyl]salicylic acid and 6-[8(Z), 11(Z), 14-pentadecatrienyl]salicylic acid.” Chemical & pharmaceutical bulletin vol. 49,1 (2001): 18-22. doi:10.1248/cpb.49.18. cited by applicant
Swamy, M.M.M., et al., Structure-inspired design of a sphingolipid mimic sphingosine-1-phosphate receptor agonist from a naturally occurring sphingomyelin synthase inhibitor. Chem Commun (Camb), 2018. 54(90): p. 12758-12761. cited by applicant
Wisastra, R et al. “Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection.” Bioorganic & medicinal chemistry vol. 21,24 (2013): 7763-78. doi: 10.1016/j.bmc.2013.10.015. cited by applicant
Wisastra, R et al. “Anacardic acid derived salicylates are inhibitors or activators of lipoxygenases.” Bioorganic & medicinal chemistry vol. 20, 16 (2012): 5027-32. doi:10.1016/j.bmc.2012.06.019. cited by applicant

edspgr.12083134